WeVote
Log In

Bill

Bill

SB 1983

Relating to the manufacture, sale, and distribution of products developed using mRNA material in the prevention or treatment of a communicable disease.

89th Legislature (2025) Introduced by Bob Hall

Texas bill regulates manufacture, sale, and distribution of mRNA-based communicable disease prevention and treatment products within state jurisdiction.

Referred to Health & Human Services
#health--general(i0385) #health--otherdiseases&medicalconditions(i0383) #immunizations(s4341) #medicine&prescriptiondrugs(s7338)
0
WeVote Research Nonpartisan
Bill Summary · SB 1983

Legislative bill overview

SB 1983 establishes regulatory frameworks governing the manufacture, sale, and distribution of mRNA-based products used to prevent or treat communicable diseases in Texas. The bill was recently filed and referred to the Health & Human Services committee for consideration during the 2025 legislative session.

Why is this important

mRNA technology has become a significant component of modern disease prevention and treatment, as demonstrated by COVID-19 vaccines and emerging therapeutics. State-level regulation of these products could affect drug approval timelines, manufacturer compliance costs, healthcare access, and Texas's relationship with federal FDA oversight—all of which impact public health infrastructure and pharmaceutical availability.

Potential points of contention

  • Federal preemption concerns: mRNA products are primarily regulated by the FDA at the federal level; state-level manufacturing or distribution requirements could create conflicts with existing federal authority or create duplicative regulatory burdens
  • Scope and definition clarity: The bill's language regarding what qualifies as "mRNA material" and which products fall under its purview remains undefined, potentially creating ambiguity for manufacturers and distributors
  • Access vs. safety trade-offs: Additional state regulations could delay product availability or increase costs, potentially limiting patient access, while supporters may argue stronger state oversight improves product safety and quality standards

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.